Cancers often release molecules into the bloodstream that pathologically alter the liver, shifting it to an inflammatory state, causing fat buildup and impairing its normal detoxifying functions, according to a study. This discovery illuminates one of cancer’s more insidious survival mechanisms and suggests the possibility of new tests and drugs for detecting and reversing this process.
In the study, published in Nature, the researchers found that a wide variety of tumor types growing outside the liver remotely reprogram the liver to a state resembling fatty liver disease via secretion of extracellular vesicles and particles (EVPs) containing fatty acids. The scientists found evidence of this process in animal models of cancer and in the livers of human cancer patients.
“Our findings show that tumors can lead to significant systemic complications including liver disease, but also suggest that these complications can be addressed with future treatments,” said the study co-senior author.
In the new study, the researchers uncovered a different set of liver changes caused by distant cancer cells which they observed in animal models of bone, skin and breast cancer that metastasize to other organs but not to the liver. The study’s key finding is that these tumors induce accumulation of fat molecules in liver cells, consequently reprogramming the liver in a way that resembles the obesity- and alcohol-related condition known as fatty liver disease.
The team also observed that reprogrammed livers have high levels of inflammation, marked by elevated level of tumor necrosis factor-α (TNF-α), and low levels of drug-metabolizing enzymes called cytochrome P450, which break down potentially toxic molecules, including many drug molecules. The observed reduction in cytochrome P450 levels could explain why cancer patients often become less tolerant of chemotherapy and other drugs as their illness progresses.
The researchers traced this liver reprogramming to EVPs that are released by the distant tumors and carry fatty acids, especially palmitic acid. When taken up by liver-resident immune cells called Kupffer cells, the fatty acid cargo triggers the production TNF-α, which consequently drives fatty liver formation.
Although the researchers principally used animal models of cancers in the study, they observed similar changes in the livers of newly diagnosed pancreatic cancer patients who later developed non-liver metastases.
“One of our more striking observations was that this EVP-induced fatty liver condition did not co-occur with liver metastases, suggesting that causing fatty liver and preparing the liver for metastasis are distinct strategies that cancers use to manipulate liver function,” said a co-first author.
The scientists suspect that the fatty liver condition benefits cancers in part by turning the liver into a lipid-based source of energy to fuel cancer growth.
“We see in liver cells not only an abnormal accumulation of fat but also a shift away from the normal processing of lipids, so that the lipids that are being produced are more advantageous to the cancer,” said the other co-senior author.
That may not be the only benefit that cancers derive from this liver alteration. “There are also crucial molecules involved in immune cell function, but their production is altered in these fatty livers, hinting that this condition may also weakens anti-tumor immunity,” said the other co-senior author.
The researchers were able to mitigate these systemic effects of tumors on the livers by implementing strategies such as blocking tumor-EVP release, inhibiting the packaging of palmitic acid into tumor EVPs, suppressing TNF-α activity, or eliminating Kupffer cells in the experimental animal models.
The researchers are further investigating the potential of implementing these strategies in human patients to block these remote effects of tumors on the liver, and exploring the possibility of utilizing the detection of palmitic acid in tumor EVPs circulating in the blood as a potential warning sign of advanced cancer.
https://www.nature.com/articles/s41586-023-06114-4
Tumor extracellular vesicles and particles induce liver metabolic dysfunction
- 1,003 views
- Added
Latest News
Functional heterogeneity of…
By newseditor
Posted 13 May
Gut bacteria produced compo…
By newseditor
Posted 13 May
Role of ECM in brain memory
By newseditor
Posted 13 May
All individuals with two co…
By newseditor
Posted 12 May
Autoantibody patterns in pa…
By newseditor
Posted 12 May
Other Top Stories
Western diet damages immune cells in digestive tracts
Read more
Sex as an important factor in nanomedicine
Read more
Pathogenic mechanism to counteract host defense
Read more
Mild COVID-19 induces lasting antibody protection
Read more
Collectivism predicts mask use during COVID-19
Read more
Protocols
Mime-seq 2.0: a method to s…
By newseditor
Posted 13 May
Improved detection of DNA r…
By newseditor
Posted 09 May
Single-cell adhesive profil…
By newseditor
Posted 07 May
Parasympathetic neurons der…
By newseditor
Posted 07 May
Non-invasive measurements o…
By newseditor
Posted 05 May
Publications
Pharmacological induction o…
By newseditor
Posted 13 May
The Effect of Glycine and N…
By newseditor
Posted 13 May
Diindoles produced from com…
By newseditor
Posted 13 May
Endothelial cell expression…
By newseditor
Posted 13 May
Senescence: A DNA damage re…
By newseditor
Posted 13 May
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar